| P50 | author | Carlo Buonerba | Q55188046 |
| P2093 | author name string | Giuseppe Di Lorenzo | |
| | Vittorio Riccio | |
| | Simone Carrano | |
| P2860 | cites work | Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer | Q49177485 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 |
| | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 |
| | Ipilimumab and its toxicities: a multidisciplinary approach | Q33777476 |
| | Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial | Q34058870 |
| | Immunotherapy for the treatment of prostate cancer | Q34186928 |
| | A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma | Q35003023 |
| | A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. | Q38396717 |
| | Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers | Q48474423 |
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 2861-2864 | |
| P577 | publication date | 2015-09-25 | |
| P1433 | published in | Future Oncology | Q2781597 |
| P1476 | title | The role of immunotherapy in oncology | |
| P478 | volume | 11 | |